RT Journal Article
T1 Premature menopause and autoimmune primary ovarian insufficiency in two international multi-center cohorts.
A1 Vogt, Elinor Chelsom
A1 Real, Francisco Gómez
A1 Husebye, Eystein Sverre
A1 Björnsdottir, Sigridur
A1 Benediktsdottir, Bryndis
A1 Bertelsen, Randi Jacobsen
A1 Demoly, Pascal
A1 Franklin, Karl Anders
A1 de Aja Gallastegui, Leire Sainz
A1 González, Francisco Javier Callejas
A1 Heinrich, Joachim
A1 Holm, Mathias
A1 Jogi, Nils Oscar
A1 Leynaert, Benedicte
A1 Lindberg, Eva
A1 Malinovschi, Andrei
A1 Martínez-Moratalla, Jesús
A1 Mayoral, Raúl Godoy
A1 Oudin, Anna
A1 Pereira-Vega, Antonio
A1 Semjen, Chantal Raherison
A1 Schlünssen, Vivi
A1 Triebner, Kai
A1 Øksnes, Marianne
K1 autoimmune
K1 premature menopause
K1 premature ovarian failure
K1 premature ovarian insufficiency
K1 primary ovarian insufficiency
AB To investigate markers of premature menopause ( Postmenopausal women were categorized according to age at menopause and self-reported reason for menopause in a cross-sectional analysis of 6870 women. Variables associated with the timing of menopause and hormone measurements of 17β-estradiol and follicle-stimulating hormone were explored using multivariable logistic regression analysis. Specific immunoprecipitating assays of steroidogenic autoantibodies against 21-hydroxylase (21-OH), side-chain cleavage enzyme (anti-SCC) and 17alpha-hydroxylase (17 OH), as well as NACHT leucine-rich-repeat protein 5 were used to identify women with likely autoimmune POI. Premature menopause was identified in 2.8% of women, and these women had higher frequencies of nulliparity (37.4% vs 19.7%), obesity (28.7% vs 21.4%), osteoporosis (17.1% vs 11.6%), hormone replacement therapy (59.1% vs 36.9%) and never smokers (60.1% vs 50.9%) (P  Idiopathic POI affects 1.1% of all women and almost half of the women with premature menopause. Autoimmunity explains 4.5% of these cases judged by positive steroidogenic autoantibodies.
SN 2049-3614
YR 2022
FD 2022-05-25
LK http://hdl.handle.net/10668/20440
UL http://hdl.handle.net/10668/20440
LA en
DS RISalud
RD Apr 8, 2025